ADIAOTCMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Adia Med, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.13−0.01 (-7.14%)
Close on Oct 19, 2026
- Market cap
- $20.98M
- P/E (TTM)
- –
- Dividend yield
- –
Adia Med, Inc. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | % of revenue | YoY |
|---|---|---|---|---|
| Adia Labs [Member] | $448.89K | $0 | 64.1% | – |
| Adia Med [Member] | $245.96K | $0 | 35.1% | – |
| Biolete [Member] | $3.39K | $6.38K | 0.5% | -46.8% |
| Corporate Segment [Member] | $2.27K | $0 | 0.3% | – |
| Operating income | FY2025 | FY2024 | YoY |
|---|---|---|---|
| Adia Labs [Member] | $148.78K | -$1.95K | -7741.7% |
| Biolete [Member] | -$247 | -$25.84K | -99.0% |
| Adia Med [Member] | -$198.89K | -$21.37K | +830.8% |
| Corporate Segment [Member] | -$316.14K | -$125.60K | +151.7% |
By product or service
| Revenue | FY2025 | FY2024 | % of revenue | YoY |
|---|---|---|---|---|
| Sales Of Prducts And Services [Member] | $700.51K | $6.38K | 100.0% | +10879.7% |
| Sales Of Biologics [Member] | $443.75K | $0 | 63.3% | – |
| Biologics [Member] | $289.59K | $0 | 41.3% | – |
| Medical Procedures [Member] | $245.60K | $0 | 35.1% | – |
| Procedures [Member] | $217.96K | $0 | 31.1% | – |
| Shipping And Delivery [Member] | $5.14K | $0 | 0.7% | – |
| Sales Of Supplements [Member] | $3.39K | $6.38K | 0.5% | -46.8% |
| Services [Member] | $2.27K | $0 | 0.3% | – |
| Supplements [Member] | $1.30K | $4.19K | 0.2% | -69.1% |
| Sales Of Ancillary Products [Member] | $360 | $0 | 0.1% | – |
By region
From the segment and revenue-disaggregation notes of Adia Med's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.